Recruiting

Adrenal Adapt

Sponsor:

Bioligent

Code:

NCT07893561

Conditions

Improves Daytime Energy Levels

Reduces Afternoon Energy Crashes and Midday Fatigue

Improves Overall Sleep Quality and Restorative Sleep

Helps People Fall Asleep Faster and Wake Less During the Night

Helps People Wake Feeling Refreshed

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Accepted

Interventions

Adrenal Adapt

Study Details

Brief summary:

This is a single-group, open-label, uncontrolled clinical trial designed to evaluate the effects of Adrenal Adapt, a commercially available dietary supplement, on sleep quality, daytime energy, stress resilience, and cognitive performance over a 12-week intervention period in 40 healthy adults aged 18-60.

Conditions

Improves Daytime Energy Levels

Reduces Afternoon Energy Crashes and Midday Fatigue

Improves Overall Sleep Quality and Restorative Sleep

Helps People Fall Asleep Faster and Wake Less During the Night

Helps People Wake Feeling Refreshed

Study ID

NCT07893561

Start date

Sep 9, 2026

Status verified date

Oct, 2026

Completion date

Dec 2, 2026

Anticipated

Primary completion date

Dec 2, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Accepted

Inclusion criteria:

  • Adults aged 18-60 years at the time of enrollment.
  • Experiencing difficulty with at least two of the following: sleep quality (including difficulty falling asleep, nighttime awakenings, or unrefreshing sleep), daytime fatigue or low energy, and/or subjective feelings of elevated stress.
  • Generally healthy - does not live with any uncontrolled chronic disease that would interfere with study participation or confound study outcomes.
  • If currently taking medications, supplements, or herbal remedies targeting sleep, stress, or energy, willing to maintain that routine unchanged for the study duration without introducing any other new products.
  • Willing to take 1 capsule of Adrenal Adapt three times daily with a meal (morning, afternoon, evening) for 12 weeks, not exceeding 3 capsules per day.
  • Willing to avoid excessive caffeine and alcohol for the duration of the study, defined as more than 400mg of caffeine per day, more than 15 alcoholic drinks per week for men and more than 7 alcoholic drinks per week for women.
  • Willing to maintain their current diet, sleep habits, and activity levels for the duration of the trial.
  • Resides in the United States with a valid shipping address.
  • Has consistent access to a smartphone or computer and a reliable internet connection sufficient to complete digital surveys.

Exclusion criteria:

  • Currently pregnant, breastfeeding, or planning to become pregnant at any point during the study period.
  • Currently taking anticoagulant medications (e.g., warfarin, heparin, or direct oral anticoagulants), as specified in the product's known contraindications.
  • Known allergy or hypersensitivity to any ingredient in Adrenal Adapt (including Hypromellose capsule shell, white rice flour, stearic acid, silicon dioxide, or any of the botanical extracts).
  • Diagnosed with a clinically significant psychiatric disorder (e.g., major depressive disorder or bipolar disorder) that could confound subjective outcome assessments or interfere with study participation.
  • Diagnosed with a sleep disorder for which pharmacological treatment has been prescribed (e.g., narcolepsy, sleep apnea treated with a CPAP device and prescription medications, insomnia disorder treated with prescription hypnotics).
  • Generated by Citruslabs · 02c23d89-a524-4659-bc54-5792f4592244 Planning to introduce any new prescription medications, supplements, or herbal products targeting sleep, stress, or energy during the study period.
  • History of substance use disorder or currently using recreational drugs that may affect sleep or stress physiology.
  • Planning surgery or a major medical procedure during the 12- week study period.
  • Currently enrolled in or planning to enroll in another research study during the study period.

Study Design

Enrollment

40 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Adrenal Adapt Arm

Interventions

Adrenal Adapt

All enrolled participants take 1 capsule of Adrenal Adapt three times daily (once in the morning with the first meal of the day, once in the afternoon with the midday meal, and once in the evening with the evening meal), not to exceed 3 capsules per day, for 12 weeks.

Primary outcome measure

  • Change in Overall Sleep Quality [ Time Frame: Baseline to Week 12 ]
  • Change in Sleep Onset Latency [ Time Frame: Baseline to Week 12 ]
  • Change in Nighttime Awakenings [ Time Frame: Baseline to Week 12 ]
  • Change in Subjective Morning Refreshment [ Time Frame: Baseline to Week 12 ]

Central Contacts and Locations

Central contacts

Patrick Renner

42424250284hello@citruslabs.com

Locations

Citruslabs

Recruiting

Las Vegas, Nevada, United States, 89118

More Information

Sponsor

Bioligent

Last update posted

Oct 26, 2026

Last verified

Oct, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-27. This information was provided to ClinicalTrials.gov by Bioligent on 2026-10-26. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.